News & Updates

Refractory Crohn’s disease responds well to risankizumab
Refractory Crohn’s disease responds well to risankizumab
09 Jan 2023

In the treatment of patients with luminal Crohn’s disease and multiple prior drug failures, risankizumab induces clinical response in about three out of four patients and steroid-free clinical remission in about half, according to a study.

Refractory Crohn’s disease responds well to risankizumab
09 Jan 2023
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
07 Jan 2023

Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.

Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
07 Jan 2023
TACE + apatinib: A potential new strategy for intermediate/advanced HCC?
TACE + apatinib: A potential new strategy for intermediate/advanced HCC?
28 Dec 2022 byRoshini Claire Anthony

In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.

TACE + apatinib: A potential new strategy for intermediate/advanced HCC?
28 Dec 2022
Coeliac disease tied to higher risk of juvenile idiopathic, rheumatoid arthritis
Coeliac disease tied to higher risk of juvenile idiopathic, rheumatoid arthritis
26 Dec 2022

Young patients with coeliac disease (CD) tend to develop juvenile idiopathic arthritis (JIA) three times more often than does the general population, while adult CD patients appear to have rheumatoid arthritis (RA) nearly twice as often, reveals a study.

Coeliac disease tied to higher risk of juvenile idiopathic, rheumatoid arthritis
26 Dec 2022